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Abstract: The incidence of diabetes is directly related to the incidence of obesity, which is at 
epidemic proportions in the US. Cardiovascular disease is a common complication of diabetes, 
which results in high morbidity and mortality. Peroxisome proliferator-activated receptors 
(PPARs) are a group of nuclear hormone receptors that regulate lipid and glucose metabolism. 
PPAR-α agonists such as fenofibrate and PPAR-γ agonists such as the thiozolidinediones have 
been used to treat dyslipidemia and insulin resistance in diabetes. Over the past few years 
research has discovered the role of PPARs in the regulation of inflammation, proliferation, and 
angiogenesis. Clinical trials looking at the effect of PPAR agonists on cardiovascular outcomes 
have produced controversial results. Studies looking at angiogenesis and proliferation in various 
animal models and cell lines have shown a wide variation in results. This may be due to the 
differential effects of PPARs on proliferation and angiogenesis in various tissues and pathologic 
states. This review discusses the role of PPARs in stimulating angiogenesis. It also reviews the 
settings in which stimulation of angiogenesis may be either beneficial or harmful.
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Introduction
Obesity, diabetes and cardiovascular disease are at epidemic proportions in the 
US.1,2 A large amount of clinical and basic research has been done to elucidate the 
pathophysiology of these disease processes. Peroxisome proliferator-activated receptors 
(PPARs) are a group of nuclear hormone receptors that control the expression of 
networks of genes regulating lipid metabolism and insulin resistance.3 They have been 
shown to affect inflammation, proliferation, immune function and angiogenesis.3 There 
are three PPAR isotypes, PPAR-α, PPAR-β/δ, and PPAR-γ. They form heterodimers 
with the retinoid X receptors and bind to specific DNA sequences, called peroxisome 
proliferator response elements (PPRE), in the promoter regions of their target genes. 
PPARs exhibit isotype-specific tissue expression patterns. PPAR-α is primarily 
expressed in organs with significant fatty acid catabolism. PPAR-β/δ is expressed in 
nearly all cell types and the level of expression seems to depend on the amount of angio-
genesis, cell proliferation, and differentiation occurring in that specific tissue.4 PPAR-γ 
is found in adipose tissue and at lower levels in immune cells vascular tissue and some 
organs. PPAR-γ exists in two protein isoforms, PPAR-γ1 and PPAR-γ2, with different 
lengths of the N-terminal. The PPAR-γ2 isoform is predominantly expressed in adipose 
tissue, whereas PPAR-γ1 is relatively widely expressed.5 Expression of each isoform is 
driven by a specific promoter that confers the distinct tissue expression patterns. There 
are also two other mRNA variants of PPAR-γ, proteins identical to PPAR-γ1: PPAR-γ    3, Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 166
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which is restricted to macrophages, adipose tissue, and colon, 
and PPAR-γ4, the tissue distribution of which is unclear at 
this time.5 Human PPAR-γ plays a critical physiological role 
as a central transcriptional regulator of both adipogenic and 
lipogenic programs. Its transcriptional activity is induced 
by the binding of endogenous and synthetic lipophilic 
ligands, which has led to the determination of many roles 
for PPAR-γ in pathological states such as type 2 diabetes, 
atherosclerosis, inflammation, and cancer. The role of 
PPARs has traditionally been recognized as antiprolifera-
tive and antiangiogenic in a large number of disease states 
including cancer and cardiovascular disease.4 These studies 
have led to clinical trials with PPAR agonists to evaluate 
their benefits in cancer and cardiovascular disease. The 
results of some of these trials especially in cardiovascular 
disease have been mixed and hence controversial. The 
results obtained with a PPAR-γ agonist pioglitazone do 
suggest a better impact on the lipid profile compared to 
rosiglitazone (the former lowers triglyceride significantly 
and has less adverse effects on low-density lipoprotein [LDL] 
cholesterol), and at least a mixed result (the primary com-
posite endpoint was not reduced significantly but myocardial 
infarction, stroke, and death were reduced by 16%), in an 
outcome trial – PROspective pioglitAzone Clinical Trial In 
macroVascular Events (PROACTIVE).6 Rosiglitazone on 
the other hand was found to increase cardiovascular events 
in a large restrospective analysis study.7 This has led to a lot 
of recent research into PPARs that is contrary to the tradi-
tional literature in their role as inhibitors of angiogenesis. 
This review will examine the role and evidence of PPARs 
as promoters of angiogenesis, the mechanisms involved, and 
the implications thereof.
Angiogenesis, type 2 diabetes,  
and cardiovascular disease
Angiogenesis is described as the formation of new capillaries 
from the existing vasculature. This process involves the 
breakdown of the extracellular matrix and formation of an 
endothelial tube. Angiogenesis is an important physiologic 
process in the female reproductive cycle, wound healing, and 
bone formation. Angiogenesis is also a crucial step in several 
disease states including cancer, diabetic retinopathy, rheuma-
toid arthritis, stroke, and ischemic coronary artery disease.8–10 
Neoangiogenesis has harmful as well as beneficial effects in 
the setting of type 2 diabetes and cardiovascular disease.10 
In the setting of diabetes, there is abnormal regulation and 
signaling of vascular endothelial growth factor (VEGF) 
and its receptor Flk-1.11 This may lead to increased levels 
of circulating VEGF, resulting in increased permeability of 
vascular structures throughout the body. In the retina, this 
results in the formation of protein-rich exudates containing 
VEGF that induces a local inflammatory response resulting 
in capillary sprouting. A similar process might take place 
in the arterial wall, thereby promoting capillary sprouting 
and plaque destabilization.12 At the same time, the lack of 
Flk-1 activation in endothelial cells and abnormal VEGF-
dependent activation of monocytes impair the arteriogenic 
response that requires monocyte recruitment, and monocyte 
and endothelial cell migration and proliferation.11 This 
could lead to a deficient angiogenic response in ischemic 
tissue. VEGF/Flk-1 signaling may also be required for bone 
marrow release of circulating endothelial progenitor cells 
that play a role in endothelial function and arteriogenesis.13 
The abnormal release of endothelial progenitors could 
further reduce arteriogenic response. This has therapeutic 
implications in terms of vascularization and survival of skin 
grafts in patients with diabetes as well as vascularization 
of the ischemic myocardium. An important mechanism by 
which PPARs seem to regulate angiogenesis is via VEGF.11,12 
It would therefore appear that PPARs have a role in regulating 
both beneficial and harmful effects of angiogenesis thereby 
leading to controversial results (Figure 1).
The other factor influencing the results of angiogenesis 
studies is the use of PPAR agonists that have pleotropic 
effects. PPAR-α agonists such as fibrates stimulate pathways 
that do not depend on PPAR-α.14 PPAR-γ agonists such as 
thiozolidinediones (TZDs) have PPARγ independent actions 
on proliferative and inflammatory pathways.14 Therefore to 
conclude that the effects of commonly used PPAR agonists 
on angiogenesis are specifically due to PPAR activation is 
at best controversial.15
PPAR-α and angiogenesis
Studies supporting antiproliferative 
properties of PPAr-α
PPAR-α agonists such as fibrates have long been used 
clinically to treat dyslipidemia. Several studies using fibrates 
have shown that they inhibit proliferation, angiogenesis and 
tumor growth.16 In the Fenofibrate Intervention in Event 
Lowering in Diabetes (FIELD) study fenofibrate treatment 
demonstrated a significant 30% reduction in the need for 
laser therapy in patients with and without known diabetic 
retinopathy, and more particularly in the first course of 
laser treatment for both macular edema and proliferative 
retinopathy.17 In addition, fenofibrate treatment was associ-
ated with less albuminuria progression and reduced risk of Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 167
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non traumatic distal amputations.17 Pozzi et al treated mice 
injected with tumor cells with Wy-14643, a selective PPAR-α 
ligand. Wy-14643 treated mice showed marked reductions 
in tumor growth and vascularization.15 All these responses 
were absent in PPAR-α-/- mice thus suggesting that these 
antiproliferative effects might be PPARα mediated. Several 
other animal studies show the antiproliferative properties of 
fenofibrate (Table 1).18,19
Studies supporting proangiogenic  
role of PPAr-α
However recent studies using specific non fibrate PPAR-α 
agonists or PPAR-α knockout mice have shown that PPAR-α 
may be involved in stimulating angiogenesis (Table 1). Biscetti 
et al used a selective synthetic PPAR-α agonist to demonstrate 
that activation of PPAR-α leads to endothelial tube formation 
in an endothelial/interstitial cell co-culture assay.20 This study 
also showed that neovascularization occurs with PPARα 
activation in a murine corneal angiogenic model. In contrast 
no angiogenesis was found in PPAR-α knockout mice treated 
with this synthetic agonist.20 In another study iloprost, an 
angiogenesis agent, was not able to induce angiogenesis in 
PPAR-α knockout mice.21 In both these studies angiogenesis 
was stimulated through a PPAR-α induced VEGF upregu-
lation. Fauconnet et al showed that activation of PPAR-α 
increased VEGF expression via a transcriptional activation 
of the VEGF promoter.22
Although the majority of studies point towards the anti-
proliferative, antiangiogenic properties of PPAR-α, this may 
be due to the use of fibrates as agonists in these experiments. 
A lot more research needs to be done using methods such as 
spontaneous PPAR-α activation, overexpression, silencing 
and knockout mice, rather than using chemical agonists and 
antagonists which might have pleotropic effects unrelated 
to PPAR-α.
PPAR-β/δ and angiogenesis
Recently developed synthetic ligands and genetically modified 
mice models for PPAR-β/δ have increased our knowledge 
of its role in metabolism, inflammation, and angiogenesis. 
A large range of naturally occurring ligands bind to 
PPAR-β/δ, including 14 to 18 carbon saturated fatty acids, 
16 to 20 carbon polyunsaturated fatty acids, prostaglandin 
A1 and carbaprostacyclin.23 However, whether any of these 
are physiological ligands is controversial. Retinoic acid 
and several synthetic ligands can also specifically activate 
PPAR-β/δ.24
Studies supporting proangiogenic  
role of PPAr-β/δ
Studies generally show that PPAR-β/δ may be involved in 
stimulating angiogenesis (Table 1). The PPAR-β/δ agonist 
GW501516 stimulated human umbilical vein endothelial 
cells proliferation and increased VEGF expression.25 
In another experiment GW501516 increased angiogenesis 
and promoted endothelial tube formation in a PPAR-β/δ 
and VEGF dependent manner.26 Gaudel et al showed that 
PPAR-β/δ activation resulted in a 1.5-fold increase in 
capillary number in mouse skeletal muscle.27 In a study of 
tissue samples obtained from human colorectal carcinomas and 
matched adjacent tissues, VEGF expression, microvascular 
density, and venous vessel invasion increased as the expres-
sion of PPAR-β/δ and cyclooxygenase (COX)-2 increased.28 
He et al performed a set of experiments in human endothelial 
progenitor cells (EPCs) which showed that impaired tube 
formation and cell proliferation induced by inactivation of 
COX-1 were rescued by treatment with a PPAR-β/δ agonist. 
Furthermore, transfection of PPAR-β/δ siRNA into EPCs 
decreased the capillary formation in vivo after transplantation 
of these human EPCs into nude mice.29 Growth of syngeneic 
PPAR-β/δ wild-type tumors was suppressed in PPAR-β/δ-/- 
mice, along with a decreased blood flow and hyperplastic 
vasculature.30 Muller et al reviewed a number of recent studies 
that suggest that stromal PPAR-β/δ regulates tumor endothelial 
cell proliferation and promotes differentiation leading to 
the properly orchestrated events required for tumor blood 
vessel formation.31 These data do suggest that PPAR-β/δ may 
indeed be proangiogenic under certain conditions.
Harmful effects
↑Proliferative retinopathy
↑Plaque instability/rupture
↑Nephropathy
↑Tumor size/spread
↓
Beneficial effects
↓Skin ischemia
↑Blood supply to myocardium
Infarct size
↓Brain ischemia
ERK1/2
PI3K
AKT
eNOS
iNOS
HIF-1
VEGF
PPARs
Increased Angiogenesis
+
+ +
+
+
Figure 1 Mechanisms by which PPArs effect angiogenesis.Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 168
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Table 1 effect of PPArs on angiogenesis
Receptor Stimulation     Inhibition    
  Type of cells/model Study outcome Ref Type of cells/model Study outcome Ref
PPAR-α endothelial/interstitial 
cell co-culture assay
↑   endothelial tube 
formation
17 Human DM2 patients ↓ proliferative retinopathy 14
↓ albuminuria
Murine corneal 
angiogenic model
↑ neovascularization 17 Porcine model 
coronary
↓ neointimal hyperplasia 15
PPAr-α knockout 
mice
↑ veGF expression
↑ angiogenesis
18 Mouse model ↓   vascular smooth muscle 
proliferation
16
Bladder cancer cells ↑ veGF expression 19 Mouse model  
cancer
↓ angiogenesis
↓ veGF expression
5966
PPAR-β/δ HUveC ↑   endothelial cell 
Proliferation
22 rats – ischemic  
injury model
↓ testicular ischemic injury
↓ erK1/2 activation
6067
HUveC ↑   endothelial tube 
formation
23 rat vascular smooth 
muscle cells
↓ proliferation
↓ migration
6168
Murine skeletal 
muscle
↑ capillary number 24 Human HaCaT 
keratinocytes
↓ cell proliferation 6269
Human colorectal 
tumor cells
↑ veGF expression
↑ vessel invasion
25 Mouse cremasteric 
endothelium
↓   leukocyte adhesion and 
migration
↓ iCAM-1 and e-selectin
6370
ePCs ↑   endothelial tube 
formation
↑   endothelial cell 
proliferation
26
PPAR-γ Bovine aortic 
endothelial cells
↑ veGF expression
↑ NO production
38 Choroidal 
endothelial cells
↓ endothelial cell proliferation
↑ differentiation
31
Cultured rat 
myofibroblasts
↑   endothelial tube 
formation
↑ veGF expression
39 HUveC ↓   endothelial cell prolifera-
tion and migration
↓ endothelial tube formation
34
Murine adipose tissue ↑ veGF expression
↑ angiopoeitin-4
40 endothelial cells ↑ apoptosis 35
rat cerebral 
ischemia model
↓ infarct size
↑ eNOS
↓ caspase-3
41 rat astrocytes ↑ apoptosis
↑ differentiation
36
Humans with DM2 ↑ veGF, ↑ iL-8
↑ angiogenin
44 rat carotid ↓ neointimal 32 hyperplasia 32
Abbreviations: DM2, diabetes mellitus type 2; ePCs, human endothelial progenitor cells; HUveC, human umbilical vein endothelial cells;   veGF, vascular endothelial 
growth factor.
Mechanisms by which PPAR-β/δ activation either 
suppresses or stimulates angiogenesis are not well studied. 
A large number of studies implicate increased VEGF and 
Flt-1 expression.32,33
PPAR-γ and angiogenesis
PPAR-γ is probably the most studied PPAR, likely due 
to the use and development of several PPAR-γ agonists 
such as thiozolidinediones in the treatment of type 2 
diabetes. Endogenous ligands for PPAR-γ include long 
chain polyunsaturated fatty acids and their derivatives, 
15-deoxy-∆12, 14-prostaglandin J2 (15d-PGJ2).4 Other 
natural ligands include nitrolinoleic acids. 15d-PGJ2 has been 
found to upregulate the expression of PPAR-γ and also the 
DNA binding and transcriptional activity.34 Synthetic ligands 
include TZDs and various nonsteroidal anti-inflammatory 
drugs.35
Studies supporting antiproliferative 
properties of PPAr-γ
PPAR-γ has widespread effects involving, inflammation, 
atherosclerosis, obesity, diabetes, and cancer.36 PPAR-γ Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 169
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agonists directly inhibit tumor cell growth, induce cell 
differentiation, and apoptosis in various cancer types 
(Table 1).37 TZDs have been shown to decrease post 
angioplasty neointimal hyperplasia in both animals and 
humans (Table 1).38,39 PPAR-γ ligands have been shown 
to inhibit and stimulate angiogenesis (Table 1). Inhibition 
by PPAR-γ ligands can occur through direct effects on the 
endothelium or through indirect effects on the net balance 
of proangiogenic and antiangiogenic mediators.37 PPAR-γ 
expressed in choroidal endothelial cells inhibits the differ-
entiation and proliferation of those cells.38,39 Rosiglitazone 
inhibited endothelial cell proliferation and migration and 
decreased VEGF-induced tubule formation in human 
umbilical vein endothelial cells.40,41 In another study 
PPAR-γ ligands stimulated endothelial cell caspase-mediated 
apoptosis.42 15d-PGJ2, an endogenous ligand of PPAR-γ, 
induces growth inhibition, differentiation, and apoptosis 
of tumor cells.43 PPAR-γ activation interrupts NF-kβ 
signaling with subsequent blockade of proinflammatory gene 
expression.43 Pioglitazone and rosiglitazone inhibit the effects 
of growth factors such as bFGF and VEGF. Endothelial cell 
migration is also inhibited by both compounds.44 Thus natural 
and synthetic ligands of PPAR-γ exhibit antiangiogenic 
properties under certain conditions.
Studies supporting proangiogenic 
role of PPAr-γ
However, PPAR- ligands have also been shown to stimulate 
the angiogenic pathway (Table 1). In bovine aortic endothelial 
cells, prolonged treatment with troglitazone increased VEGF 
and endothelial nitric oxide (NO) production with no change 
in endothelial nitric oxide synthase (eNOS) expression.45 
In cultured rat myofibroblasts, activation of PPAR-γ by 
troglitazone and 15-dPGJ2 induced VEGF expression and 
augmented tubule formation.46 In mice treated with rosigli-
tazone, angiogenesis was stimulated in adipose tissue with 
increased expression of VEGF and angiopoeitin-4 (Ang-4). 
Ang-4 stimulated endothelial cell growth and tubule forma-
tion.47 In rats with focal cerebral ischemia, rosiglitazone 
treatment enhanced neurologic improvement and reduced 
the infarct size by reducing caspase-3 activity, increas-
ing the number of endothelial cells, and increasing eNOS 
expression.48 In the setting of diabetes, PPAR-γ agonists 
may promote revascularization of ischemic tissue. Diabetic 
mice with induced unilateral hind limb ischemia, when 
treated with pioglitazone showed normalization of VEGF, 
upregulation of eNOS activity, and partial restoration of 
blood flow recovery.49 In mice treated with pioglitazone, 
VEGR-receptor-2 positive EPCs were upregulated and 
migratory capacity was increased. In vivo angiogenesis was 
increased 2-fold.50 In an endothelial/interstitial cell co-culture 
assay, treatment with PPAR-γ agonists stimulated production 
of VEGF. In the same study, corneas treated with the same 
PPAR-γ agonists increased phosphorylation of eNOS.20
Few studies have evaluated angiogenesis in humans. 
Pioglitazone treatment has been shown to increase serum VEGF, 
IL-8, and angiogenin levels in patients with type 2 diabetes.51 
In another study thiozolidinedione use in patients with type 2 
diabetes was associated with diabetic macular edema.52
PGC-1α and angiogenesis
Peroxisome proliferator-activated receptor (PPAR)-gamma 
coactivator 1alpha (PGC-1α) is a nuclear transcriptional 
coactivator that regulates several important metabolic 
processes, including mitochondrial biogenesis, adaptive 
thermogenesis, respiration, insulin secretion and gluconeo-
genesis.53 PGC-1α also co-activates PPAR-α, PPAR-β/δ, 
and PPAR-γ which are important transcription factors of 
genes regulating lipid and glucose metabolism.53 Recently 
Arany and colleagues have shown that PGC-1α stimulates 
angiogenesis in ischemic tissues. Using a combination of 
muscle cell assays and genetically modified mice that over 
or underexpess PGC-1α, they showed that PGC-1α is a 
powerful inducer of VEGF expression. PGC-1α did not 
involve HIF-1 but activated the nuclear receptor, estrogen-
related receptor-α (ERR-α).33 PGC-1α-/- mice are viable, 
suggesting that PGC-1α is not essential in embryonic 
vascularization but they show a striking failure to reconstitute 
blood flow in a normal manner to the limb after an ischaemic 
insult.54 Transgenic expression of PGC-1α in skeletal muscle 
is protective against ischemic insults. This suggests that 
PGC-1α plays a more important role in a disease state rather 
than a physiologically healthy state.
Mechanisms by which PPARs  
may stimulate angiogenesis
PPARs seem to have a protective role in ischemic tissues, 
including brain, cardiac and skin. A part of this may be 
by stimulating angiogenesis and improving blood supply. 
Hypoxia is a trigger for the development of angiogenesis. 
One of the key mediators in hypoxia-induced angiogenesis is 
hypoxia inducible factor (HIF-1), which is induced in hypoxic 
cells and binds to hypoxia response element (HRE). HIF-1 
mediates the transcriptional activation of several genes that 
promote angiogenesis, including VEGF, angiopoeitin (Ang-1, 
Ang-2), and matrix metalloproteinases (MMP-2, MMP-9).55 Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2009:2 170
Desouza et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
15-deoxy-delta(12, 14)-prostaglandin J(2) (15d-PGJ(2)), 
a PPAR-γ agonist, has been shown to induce HIF-1 expres-
sion and thereby angiogenesis (Figure 1).34 However piogli-
tazone has been shown to suppress the induction of HIF-1.56 
Conditions that influence the stimulation or suppression of 
HIF activation by PPAR-γ are largely unknown.
Several studies suggest that eNOS synthase activation 
is required for angiogenesis that may be protective under 
certain conditions.57–59 In one study pioglitazone reduced 
the myocardial infarct size in part via activation of eNOS.60 
PPAR-α activation has also been shown to protect the type 2 
diabetic rat myocardium against ischemia-reperfusion injury 
via the activation of the NO pathway (Table 1, Figure 1).61 
However, stimulation of the inducible nitric oxide (iNOS) 
pathway can lead to undesirable angiogenesis that may 
be contribute to pathological states such as proliferative 
retinopathy. PPARs in fact have been shown to suppress iNOS 
expression, thereby suppressing undesirable angiogenesis.62,63 
Here again the factors that allow for activation of eNOS and 
suppression of iNOS is largely unknown.
The most studied pathway by which PPARs may stimulate 
angiogenesis is the VEGF pathway. VEGF can stimulate 
angiogenesis via stimulation of the ERK1/2 pathway. 
PPAR-β/δ activation has been shown to increase VEGF 
expression and thereby stimulate angiogenesis (Figure 1).26 
In some studies PPAR-α and PPAR-γ have also been shown 
to increase VEGF expression.47,48 However the majority of 
studies still show that PPAR activation suppresses VEGF 
expression. The end result of whether PPAR activation 
suppresses or stimulates VEGF expression seems to lie in 
the pathological condition in which its actions are observed 
(Figure 1). It is likely that PPAR activation results in increased 
VEGF expression in conditions where new blood vessel 
formation is required, such as ischemic skin flaps, brain, 
or cardiac tissue ischemia. On the other hand, pathological 
angiogenesis such as in the eye or within an atherosclerotic 
plaque is suppressed by PPAR activation via a suppression 
of VEGF (Figure 1).
Recently some studies indicate that PPARs may increase 
the expression and activation of the phosphatidylinositol-
3-kinase (PI3K/AKT) pathway.61,64 The PI3K/AKT pathway 
stimulates angiogenesis.59,65 Again the majority of studies 
show that PPAR activation inhibits PI3K/AKT activation.
It is very likely that a large amount of variation found in 
different studies is due to the use of agonists and antagonists 
of the PPAR receptors that exhibit direct PPAR-independent 
effects. Most study designs do not distinguish between 
direct effects and indirect effects of various pharmacological 
agonists/antagonist used. Fibrates and TZDs have both been 
shown to have direct independent effects on inflammation, 
proliferation and angiogenesis. Hence it is difficult to 
conclude that all the pro and antiangiogenic effects seen in 
various studies are a result of PPAR activation exclusively.
Clinical significance and conclusions
Some compounds such as TZDs and fibrates are routinely 
used in patients with diabetes, dyslipidemia, and cardiovas-
cular disease. Other compounds such as partial agonists or 
dual agonists of PPAR-α and PPAR-γ are in development. 
The effects of these newer compounds, on angiogenesis and 
cardiovascular disease are yet to be determined. Current 
evidence from clinical trials suggest a mixed picture. TZD 
treatment in patients with type 2 diabetes has been shown 
to be associated with macular edema. On the other hand, 
the FIELD study using fenofibrate showed a decrease in the 
need for laser treatments in patients with diabetic retinopathy. 
The PROACTIVE study showed that pioglitazone trended to 
decrease certain cardiovascular endpoints. In some studies, 
rosiglitazone increased the risk of cardiovascular events. 
In other studies such as ACCORD and VADT, TZD treatment 
was not associated with increased cardiovascular event risk. 
Several factors, including the study design, PPAR receptor 
affinity, and the PPAR-independent actions of these com-
pounds, possibly play a role in the differences in results seen. 
The duration of the pathological state and the vasculature of 
the effected organ likely play a role in whether PPARs prove 
beneficial or harmful. In conclusion it may be prudent to 
summarize that at this point the evidence suggests that PPARs 
can either stimulate or inhibit angiogenesis, depending on 
the biological context and pathological process.
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